← ANALYST RATINGS · TIPRANKS
SELLAS Life Sciences Group (SLS): analyst forecast and price target
Analyst consensus
0 Buy0 Hold0 Sell
Ratings of 0 analysts in the last 3 months · top analysts only12-month forecast
Based on 0 price targets given in the last 3 months, the average target is —, the highest —, the lowest —. The average is — from the last price of $9.98.
Analyst ratings 2
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.00 → $11.50−4.2% | Hold | +15.2% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $12.00 → $11.50−4.2% | Hold | +15.2% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.00 → $11.50−4.2% | Hold | +15.2% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.00 → $11.50−4.2% | Hold | +15.2% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $11.00 → $10.50−4.5% | Sell | +5.2% | Downgrade | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $11.50 → $12.00+4.3% | Hold | +20.2% | Reiterated | 13.10.26on TipRanks Oct 12 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.50 → $12.00+4.3% | Hold | +20.2% | Reiterated | 13.10.26on TipRanks Oct 12 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $11.50 → $12.00+4.3% | Hold | +20.2% | Reiterated | 13.10.26on TipRanks Oct 12 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $11.50 → $12.00+4.3% | Hold | +20.2% | Reiterated | 13.10.26on TipRanks Oct 12 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $10.50 → $11.00+4.8% | Sell | +10.2% | Downgrade | 13.10.26on TipRanks Oct 12 23:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.00 → $11.50−4.2% | Hold | +15.2% | Reiterated | 09.10.26on TipRanks Oct 8 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.00 → $11.50−4.2% | Hold | +15.2% | Reiterated | 09.10.26on TipRanks Oct 8 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.00 → $11.50−4.2% | Hold | +15.2% | Reiterated | 09.10.26on TipRanks Oct 8 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $11.00 → $10.50−4.5% | Sell | +5.2% | Downgrade | 09.10.26on TipRanks Oct 8 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $12.00 → $11.50−4.2% | Hold | +15.2% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $11.50 → $11.00−4.3% | Hold | +10.2% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $11.50 → $12.00+4.3% | Hold | +20.2% | Reiterated | 05.10.26on TipRanks Oct 4 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.50 → $12.00+4.3% | Hold | +20.2% | Reiterated | 05.10.26on TipRanks Oct 4 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $11.50 → $12.00+4.3% | Hold | +20.2% | Reiterated | 05.10.26on TipRanks Oct 4 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $11.00 → $11.50+4.5% | Hold | +15.2% | Reiterated | 05.10.26on TipRanks Oct 4 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $11.50 → $12.00+4.3% | Hold | +20.2% | Reiterated | 05.10.26on TipRanks Oct 4 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $10.50 → $11.00+4.8% | Sell | +10.2% | Downgrade | 05.10.26on TipRanks Oct 4 23:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.00 → $11.50−4.2% | Hold | +15.2% | Reiterated | 03.10.26on TipRanks Oct 2 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.00 → $11.50−4.2% | Hold | +15.2% | Reiterated | 03.10.26on TipRanks Oct 2 23:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.00 | Hold | +20.2% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.50 | Hold | +15.2% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.00 → $11.50−4.2% | Hold | +15.2% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $11.00 | Hold | +10.2% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.00 | Hold | +20.2% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $11.00 → $10.50−4.5% | Sell | +5.2% | Downgrade | 01.10.26on TipRanks Sep 30 23:05 | — | |
| Jason McCarthy★★★★★★★★★★#12398 · hits 30% · avg −13.6% | Maxim Group | $30.00 | Buy | +200.6% | Reiterated | 19.08.26on TipRanks Aug 20 10:55 | +5.5%next day −2.4% · 5 days −0.5% | ↗ |
| James Molloy★★★★★★★★★★#12352 · hits 25% · avg −19.8% | Alliance Global Partners | $10.00 → $25.00+150.0% | Buy | +150.5% | Reiterated | 06.07.26on TipRanks 07:13 | −7.8%next day −2.7% · 5 days −9.2% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering SELLAS Life Sciences Group
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $27.50 at a price of $12.31 (+123.4%); now: $30.00 at $9.98 (+200.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.05 (from $-0.05 to $-0.05). Last quarter: $-0.05.
Best top-analyst consensus in the sector · Healthcare
About SELLAS Life Sciences Group
- CEO: Angelos Stergiou
- Employees: 13
- 7 Times Square, New York, NY, 10036, US
- www.sellaslifesciences.com
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Data from the stock’s TipRanks forecast page, read 429 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗